research High Response Rate to Bexxar in Advanced Stage Prior Treatment-Resistant Follicular Lymphoma
This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

